

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/192424 A1

(51) International Patent Classification:

C07D 471/08 (2006.01) C07D 519/00 (2006.01)
C07D 495/10 (2006.01) A61P 35/00 (2006.01)
C07D 495/20 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/020319

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

15 March 2024 (15.03.2024)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,475 15 March 2023 (15.03.2023) US
63/508,213 14 June 2023 (14.06.2023) US

(71) Applicant: QUANTA THERAPEUTICS, INC. [US/US];
2 Tower Place, Floor 14, South San Francisco, California
94080 (US).

(72) Inventors: LIN, Hong; 2 Tower Place, Floor 14, South
San Francisco, California 94080 (US). LUENGO, Juan;
2 Tower Place, Floor 14, South San Francisco, California
94080 (US). HOSPITAL, Audrey; 2 Tower Place, Floor
14, South San Francisco, California 94080 (US). ZENG,
Jin; 2 Tower Place, Floor 14, South San Francisco, Califor-
nia 94080 (US). GAN, Pei; 2 Tower Place, Floor 14, South
San Francisco, California 94080 (US).

(74) Agent: MARTINEZ, Jose; Wilson Sonsini Goodrich &
Rosati, P.C., 650 Page Mill Road, Palo Alto, California
94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: KRAS MODULATORS AND USES THEREOF

(57) Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS GD12 and/or other G12 mutants.

WO 2024/192424 A1